CeriBell, Inc. (CBLL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Ceribell's earnings call presents a positive outlook with raised revenue guidance, strong gross margins, and strategic supply chain adjustments. Their market expansion into pediatrics and neonates, coupled with a new 510(k) clearance, enhances growth prospects. While competition and IP litigation pose risks, they haven't significantly impacted performance. The Q&A section reveals optimism about account growth and strategic partnerships, with some concerns about resource limitations and competition. Overall, the company's strategic initiatives and optimistic guidance suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Total Revenue $22.6 million for Q3 2025, a 31% increase from $17.2 million in Q3 2024. The increase is primarily driven by increased adoption of the Ceribell system across new and existing accounts.
Product Revenue $17 million for Q3 2025, a 28% increase from $13.3 million in Q3 2024. The growth was achieved despite abnormally high purchases relative to usage in Q3 2024, which led to excess product revenue during the comparison period.
Subscription Revenue $5.6 million for Q3 2025, a 44% increase from $3.9 million in Q3 2024. This reflects deeper penetration and increased usage per account year-over-year.
Gross Margin 88% for Q3 2025, compared to 87% in Q3 2024. The increase is attributed to operational efficiencies, though future margins may be impacted by tariffs on products originating in China.
Operating Expenses $34.6 million for Q3 2025, a 39% increase from $24.9 million in Q3 2024. The rise is due to investments in the commercial organization, increased headcount, legal expenses, and costs related to operating as a public company.
Net Loss $13.5 million for Q3 2025, compared to $10.4 million in Q3 2024. The increase in net loss is attributed to higher operating expenses and investments in growth initiatives.
Cash, Cash Equivalents, and Marketable Securities $168.5 million as of September 30, 2025. The company remains confident in achieving cash flow breakeven without raising additional capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pediatric Clarity: Received 510(k) clearance for pediatric population, making it the only seizure detection algorithm cleared for patients 1 year and older. Pilot ongoing with full launch anticipated next year.
Neonatal Application of Clarity: Development on track with anticipated market launch in 2026. Hardware already launched at multiple sites.
Delirium Algorithm: Development progressing as planned, targeting a market with no commercially available diagnostic device for ICU patients.
Market Opportunity: Current addressable market for seizure detection is $2 billion, with an additional $400 million from pediatric and neonatal products.
Expansion into VA System: Received FedRAMP High Authorization, providing access to nearly 200 VA hospitals. VA system plans to expand usage of Ceribell system.
Revenue Growth: Q3 2025 revenue was $22.6 million, a 31% increase year-over-year. Full-year 2025 revenue guidance raised to $87-$89 million, representing 34% growth at midpoint.
Account Growth: Active accounts increased to 615 as of September 30, 2025, marking the largest sequential increase since becoming a public company.
Gross Margin: Maintained gross margin of 88% in Q3 2025, with mid-80% range expected for full year 2026.
Point-of-Care EEG Standardization: Focused on establishing point-of-care EEG as a new standard of care for seizure management in acute care settings.
Multimodal System Development: Plans to expand detection capabilities to conditions like delirium and stroke, aiming to make EEG a vital sign in acute care.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Tariff Risks: The company faces increased tariffs on products originating in China, which could impact gross margins. Although steps have been taken to establish a manufacturing line in Vietnam, the company remains exposed to potential changes in trade policies.
Supply Chain Disruptions: The company has taken steps to strengthen its supply chain by diversifying manufacturing locations, but any disruptions in these new facilities could impact operations and product availability.
Market Penetration Challenges: Despite growth, the company is only 3% penetrated into its core market in the U.S., with over 5,000 hospitals yet to adopt its system. Expanding market penetration remains a significant challenge.
Operational Costs: Operating expenses have increased by 39% year-over-year, driven by investments in commercial organization, headcount expansion, and legal expenses. This could pressure financial performance if revenue growth slows.
Cash Flow and Financial Sustainability: The company reported a net loss of $13.5 million for Q3 2025 and is not yet cash flow positive. While it has sufficient cash reserves, achieving cash flow breakeven is critical to long-term sustainability.
Competitive Pressures: The company operates in a competitive market and must continue to invest in product development and provider education to maintain its leadership position.
Adoption and Utilization Risks: The success of the Ceribell system depends on its adoption and utilization by hospitals. Delays in adoption or lower-than-expected utilization rates could impact revenue growth.
Product Development Risks: The company is investing in new products for pediatric and neonatal populations, as well as algorithms for conditions like delirium and stroke. Delays or failures in these developments could hinder market expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2025 Revenue Guidance: Ceribell has raised its full-year 2025 revenue guidance to $87 million to $89 million, representing 34% year-over-year growth at the midpoint.
Market Opportunity Expansion: The addition of pediatric and neonatal products is expected to expand the current addressable market opportunity of $2 billion by approximately $400 million, with a full launch anticipated next year.
Neonatal Application Development: The neonatal application of Clarity is on track for market introduction in 2026.
Delirium Algorithm Development: Development of a delirium algorithm remains on track, targeting a market with no commercially available diagnostic device. Further details on the opportunity and commercial strategy are expected in the coming quarters.
Gross Margin Outlook: Gross margins are expected to remain in the mid-80% range for the full year 2026, assuming no changes to proposed tariffs.
Revenue Growth Drivers: Revenue growth is driven by increased adoption of the Ceribell system across new and existing accounts, with a healthy backlog of accounts issuing purchase orders.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the company's early thoughts on 2026 regarding account additions, utilization, and pricing, especially with the NTAP expiring next year?
A:The company is not providing commentary on 2026 at this time. They will provide guidance in future calls. The fundamentals of the business, such as adding new accounts and driving usage, will remain consistent drivers. Pricing has shown consistency, with an increase in Clarity ASP due to more recorders being used in existing sites, and they expect to maintain strong pricing discipline.
Q:How does the company plan to launch the neonatal opportunity in 2026?
A:The company plans to expand into both new neonatal accounts and existing accounts. Out of 850 Level 3 and Level 4 NICUs in the U.S., their installed base already includes 200 NICUs, which will focus on departmental expansion. They also see opportunities in 280 children's hospitals and Level 3 community hospitals, which often lack EEG capabilities, driving new account additions.
Q:What progress has the company made in penetrating accounts and educating hospital components?
A:The company continues to drive account acquisition and utilization. Initiatives include encouraging teams to bring additional recorders to existing accounts, partnering with physicians on protocolization of patient populations (e.g., cardiac arrest, post-hemorrhagic stroke), and providing continued education to physicians and nurses. They also engage administrators quarterly to demonstrate the economic value of their product using clinical data.
Q:How is the company thinking about revenue versus OpEx growth in the short and medium term, and progress towards cash flow breakeven?
A:The company raised more than intended during its IPO and invested in expanding its commercial infrastructure. They expect the size of expansion to moderate in the coming year, with investments made this year generating impact in 2026. With an 88% gross margin and strong control over investments, they have flexibility to adapt their strategy to maintain a sufficient cash cushion.
Q:What is the utilization growth across accounts by tenure, and are older accounts continuously growing in utilization?
A:Utilization growth in older accounts is driven by external guidelines, departmental expansion, and internal execution. Hospitals are gradually adopting protocols for different patient populations, and even top accounts are not fully utilizing the product in all departments. The company is also focusing on training providers, including night shifts, to ensure consistent usage.
Q:How does the company plan to expand further into current accounts, and what are the barriers?
A:The company plans to expand into new departments and implement protocols in current accounts. Barriers include resource limitations on both the company's and hospitals' ends, as well as competing priorities like updating hospital systems. They believe strong guideline recommendations and clinical evidence will help overcome these barriers over time.
Q:What is the importance of the new 510(k) clearance on the headcap?
A:The new 510(k) clearance specifies that the headcap is approved for both preterm and term neonates, addressing feedback from physicians and nurses who wanted more specific FDA clearance for this vulnerable population. This clearance aligns with the company's strategy to refine products based on pilot feedback and prepares the product for full commercialization.
Q:What is the status of the new customer account pipeline and potential for account growth in 2026?
A:The customer account pipeline is growing, reflecting investments in the commercial organization and increasing appreciation for the technology. The company measures engagement at various stages before accounts go live and expects continued account growth in 2026.
Q:How is the company positioned with IDNs or healthcare systems?
A:The company has seen strong growth from partnerships with hospital systems and anticipates even greater opportunities ahead. Historically, they engaged with individual hospitals but are now building a hospital system sales team to coordinate bottom-up and top-down sales efforts. They plan to continue executing this strategy to become better partners for customers.
Q:What drives the lower end versus the higher end of the company's guidance range?
A:The guidance range reflects risk calibration. The company aims to provide numbers they are confident in achieving, with the lower end being extremely conservative to account for unknowns. For example, Q4 seasonality is expected to be stronger than Q3.
Q:What is the update on the sales force and account additions?
A:The company has not made significant changes to its commercial strategy, with mid-50s territories for TMs and continued investment in CAMs. Account additions are driven by new hires becoming productive and reflect the company's expected outcomes.
Q:Will the company start showing leverage in the P&L?
A:Leverage in the P&L will depend on strategic decisions to invest in growth opportunities. If such decisions are made, the company will communicate them clearly to investors.
Q:What is the update on competition and IP litigation?
A:Competition activity increased significantly in Q1 and Q2 but remained stable in Q3. The company has not seen a meaningful impact on performance due to competition. Regarding IP litigation, the ITC has outlined milestones, with a decision expected in September next year and a final ruling in January 2027, though delays are anticipated due to the government shutdown.
Q:What is the impact of shifting manufacturing to Vietnam on gross margins?
A:The shift to Vietnam will impact gross margins starting next year. Q4 will rely on pre-tariff and China inventory, but Vietnam inventory with lower tariff rates will contribute to maintaining mid-80% gross margins in 2026.
Q:What is the update on the VA channel?
A:The VA has a rigorous pilot and rollout process. Initial pilots have been successful, and the company is confirmed to roll out a larger cohort of VA accounts in the next couple of quarters. This represents one of the largest top-down rollouts in the company's history.
Q:What is the update on neonatal hardware utilization without Clarity?
A:The pilot phase focused on population discussions, signal quality, and ease of use rather than account-level utilization. Initial feedback has been positive, with case studies showing early seizure detection and avoidance of unnecessary medication. The company aims to bring the full product to market in 2026.
Q:What are the utilization trends across departments?
A:Utilization growth is broad, driven by departmental expansion, protocolization, and use in less-penetrated areas like emergency departments. No single driver accounts for the majority of growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific commentary on 2026, including account additions, utilization, and pricing, stating that guidance will be provided in future calls. They also did not provide quantitative details on the new customer account pipeline or specific numbers related to VA accounts. Additionally, they did not disclose the exact impact of competition on account losses or wins, nor did they provide detailed updates on IP litigation timelines beyond general expectations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
Ceribell system
Clarity market
Clarity status
EEG hour
EEG seizure
EEG standard
Founder President
President CEO
VA system
access
account purchase
account usage
addition
adoption Ceribell
base account
care EEG
care patient
clearance
delirium stroke
education
epilepticus patient
evidence generation
hospital point
market opportunity
mission point
momentum
need patient
patient market
patient risk
pilot
point care
practice account
progress account
remainder
reminder
replication
sale infrastructure
setting patient
site
today Ceribell
track development
vision
CBLL Transcript
CeriBell, Inc. (CBLL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary indicates strong financial performance with expectations of 15-20% revenue growth and stable margins. Product development and market expansion strategies are robust, with a focus on neurodiagnostics. The Q&A highlights investments in future growth, positive momentum in new segments, and strong gross margins. Despite higher OpEx due to litigation, the outlook remains optimistic. No major negative trends or uncertainties were identified, and the overall sentiment from analysts was positive, suggesting a likely stock price increase.
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary shows strong financial performance with a 15% revenue increase and improved gross margins. Strategic initiatives and revenue guidance are optimistic, with a raised full-year guidance and market expansion plans. Although there are no shareholder return plans mentioned, the positive financial metrics and growth strategies outweigh potential risks, leading to an overall positive sentiment.
Caris Life Sciences, Inc. (CAI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
